-
1
-
-
78049485263
-
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
-
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
-
(2010)
Int J Cancer
, vol.127
, pp. 2893-2917
-
-
Ferlay, J.1
Shin, H.R.2
Bray, F.3
-
3
-
-
77952583078
-
Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
-
Gridelli C, Ardizzoni A, Douillard J-Y, et al. Recent issues in first-line treatment of advanced non-small-cell lung cancer: results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer 2010;68:319-31
-
(2010)
Lung Cancer
, vol.68
, pp. 319-331
-
-
Gridelli, C.1
Ardizzoni, A.2
Douillard, J.-Y.3
-
4
-
-
33846523617
-
Targeted anti-mitotic therapies: Can we improve on tubulin agents?
-
DOI 10.1038/nrc2049, PII NRC2049
-
Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007;7:107-17 (Pubitemid 46160987)
-
(2007)
Nature Reviews Cancer
, vol.7
, Issue.2
, pp. 107-117
-
-
Jackson, J.R.1
Patrick, D.R.2
Dar, M.M.3
Huang, P.S.4
-
5
-
-
63449117144
-
Beyond taxanes: A review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins
-
Harrison MR, Holen KD, Liu G. Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol 2009;7(1):54-64
-
(2009)
Clin Adv Hematol Oncol
, vol.7
, Issue.1
, pp. 54-64
-
-
Harrison, M.R.1
Holen, K.D.2
Liu, G.3
-
6
-
-
0029745777
-
Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel
-
Milross CG, Mason KA, Hunter NR, et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996;88:1308-14 (Pubitemid 26301619)
-
(1996)
Journal of the National Cancer Institute
, vol.88
, Issue.18
, pp. 1308-1314
-
-
Milross, C.G.1
Mason, K.A.2
Hunter, N.R.3
Chung, W.-K.4
Peters, L.J.5
Milas, L.6
-
7
-
-
33747887418
-
Nab-paclitaxel-, a novel, Cremophor- EL-free albumin-bound particle form of paclitaxel for the treatment of advanced non-small cell lung cancer
-
Green MR, Manikhas GM, Orlov S, et al. Nab-paclitaxel-, a novel, Cremophor- EL-free albumin-bound particle form of paclitaxel for the treatment of advanced non-small cell lung cancer. Ann Oncol 2006;17(8):1263-8
-
(2006)
Ann Oncol
, vol.17
, Issue.8
, pp. 1263-1268
-
-
Green, M.R.1
Manikhas, G.M.2
Orlov, S.3
-
8
-
-
39149105016
-
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer
-
DOI 10.1200/JCO.2007.10.8605
-
Rizvi NA, Riely GJ, Azzoli CG, et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV nonsmall-cell lung cancer. J Clin Oncol 2008;26:639-43 (Pubitemid 351264360)
-
(2008)
Journal of Clinical Oncology
, vol.26
, Issue.4
, pp. 639-643
-
-
Rizvi, N.A.1
Riely, G.J.2
Azzoli, C.G.3
Miller, V.A.4
Ng, K.K.5
Fiore, J.6
Chia, G.7
Brower, M.8
Heelan, R.9
Hawkins, M.J.10
Kris, M.G.11
-
9
-
-
77953150067
-
A dose finding study of weekly and every-3-week nab-paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer
-
Socinski MA, Manikhas GM, Stroyakovsky DL, et al. A dose finding study of weekly and every-3-week nab-paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5:852-61
-
(2010)
J Thorac Oncol
, vol.5
, pp. 852-861
-
-
Socinski, M.A.1
Manikhas, G.M.2
Stroyakovsky, D.L.3
-
10
-
-
84863957748
-
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel and carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial
-
Socinski MA, Bondarenko I, Karaseva N, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel and carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012;30:2055-62
-
(2012)
J Clin Oncol
, vol.30
, pp. 2055-2062
-
-
Socinski, M.A.1
Bondarenko, I.2
Karaseva, N.3
-
11
-
-
84873866422
-
Safety and efficacy of weekly nab- paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer
-
Socinski MA, Langer CJ, Okamoto I, et al. Safety and efficacy of weekly nab- paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol 2013;24(2):314-21
-
(2013)
Ann Oncol
, vol.24
, Issue.2
, pp. 314-321
-
-
Socinski, M.A.1
Langer, C.J.2
Okamoto, I.3
-
12
-
-
74249105385
-
Phase II trial of albumin-bound paclitaxel + carboplatin + bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer
-
Reynolds C, Barrera D, Jotte R, et al. Phase II trial of albumin-bound paclitaxel + carboplatin + bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2009;4(12):1-7
-
(2009)
J Thorac Oncol
, vol.4
, Issue.12
, pp. 1-7
-
-
Reynolds, C.1
Barrera, D.2
Jotte, R.3
-
13
-
-
84874602796
-
In vivo assessment of the effects of bevacizumab in advanced non-small cell lung cancer (NSCLC)
-
Heist RS, Duda GD, Sahani D, et al. In vivo assessment of the effects of bevacizumab in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(15s Suppl):abstract 7612
-
(2010)
J Clin Oncol
, vol.28
, Issue.15 SUPPL.
-
-
Heist, R.S.1
Duda, G.D.2
Sahani, D.3
-
14
-
-
3042701597
-
Epothilones: Mechanism of action and biologic activity
-
DOI 10.1200/JCO.2004.12.001
-
Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004;22(10):2015-25 (Pubitemid 41095195)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.10
, pp. 2015-2025
-
-
Goodin, S.1
Kane, M.P.2
Rubin, E.H.3
-
15
-
-
78650236850
-
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
-
Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011;71:3-10
-
(2011)
Lung Cancer
, vol.71
, pp. 3-10
-
-
Chang, A.1
-
16
-
-
38449091336
-
Potential clinical applications of epothilones: A review of phase II studies
-
Larkin JM, Kaye SB. Potential clinical applications of epothilones: a review of phase II studies. Ann Oncol 2007;18(Suppl 5):v28-34
-
(2007)
Ann Oncol
, vol.18
, Issue.SUPPL. 5
-
-
Larkin, J.M.1
Kaye, S.B.2
-
17
-
-
12144285977
-
Phase I Clinical and Pharmacokinetic Study of BMS-247550, a Novel Derivative of Epothilone B, in Solid Tumors
-
DOI 10.1158/1078-0432.CCR-0919-03
-
Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004;10:1289-98 (Pubitemid 38365219)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.4
, pp. 1289-1298
-
-
Mani, S.1
McDaid, H.2
Hamilton, A.3
Hochster, H.4
Cohen, M.B.5
Khabelle, D.6
Griffin, T.7
Lebwohl, D.E.8
Liebes, L.9
Muggia, F.10
Horwitz, S.B.11
-
18
-
-
0038811741
-
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days
-
DOI 10.1200/JCO.2003.03.063
-
Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003;21:1866-73 (Pubitemid 46638601)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.9
, pp. 1866-1873
-
-
Abraham, J.1
Agrawal, M.2
Bakke, S.3
Rutt, A.4
Edgerly, M.5
Balis, F.M.6
Widemann, B.7
Davis, L.8
Damle, B.9
Sonnichsen, D.10
Lebwohl, D.11
Bates, S.12
Kotz, H.13
Fojo, T.14
-
19
-
-
20244376916
-
A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days
-
DOI 10.1002/cncr.20977
-
Zhuang S, Agrawal M, Edgerly M, et al. A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 2005;103:1932-8 (Pubitemid 40563267)
-
(2005)
Cancer
, vol.103
, Issue.9
, pp. 1932-1938
-
-
Zhuang, S.H.1
Agrawal, M.2
Edgerly, M.3
Bakke, S.4
Kotz, H.5
Thambi, P.6
Rutt, A.7
Balis, F.M.8
Bates, S.9
Fojo, T.10
-
20
-
-
34248183039
-
Ixabepilone given weekly in patients with advanced malignancies: Final efficacy and safety results of a phase i trial
-
abstract
-
Dickson N, Peck R, Wu C, Burris H. Ixabepilone given weekly in patients with advanced malignancies: final efficacy and safety results of a phase I trial. Proc Amer Soc Clin Oncol 2006;24:abstract 2040
-
(2006)
Proc Amer Soc Clin Oncol
, vol.24
, pp. 2040
-
-
Dickson, N.1
Peck, R.2
Wu, C.3
Burris, H.4
-
21
-
-
34548158974
-
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy
-
DOI 10.1200/JCO.2006.09.7097
-
Vansteenkiste J, Lara PN, Le Chevalier T, et al. Phase II clinical trial of the epothilone B analog ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007;25:3448-55 (Pubitemid 47310882)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.23
, pp. 3448-3455
-
-
Vansteenkiste, J.1
Lara Jr., P.N.2
Le Chevalier, T.3
Breton, J.-L.4
Bonomi, P.5
Sandler, A.B.6
Socinski, M.A.7
Delbaldo, C.8
McHenry, B.9
Lebwohl, D.10
Peck, R.11
Edelman, M.12
-
22
-
-
58149355287
-
A phase i and pharmacokinetic study of ixabepilone in combination with carboplatin in patients with advanced solid malignancies
-
Plummer R, Woll P, Fyfe D, et al. A phase I and pharmacokinetic study of ixabepilone in combination with carboplatin in patients with advanced solid malignancies. Clin Cancer Res 2008;14:8288-94
-
(2008)
Clin Cancer Res
, vol.14
, pp. 8288-8294
-
-
Plummer, R.1
Woll, P.2
Fyfe, D.3
-
23
-
-
84866155376
-
Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer
-
Spigel DR, Greco FA, Waterhouse DM, et al. Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer. Lung Cancer 2012;78:70-5
-
(2012)
Lung Cancer
, vol.78
, pp. 70-75
-
-
Spigel, D.R.1
Greco, F.A.2
Waterhouse, D.M.3
-
24
-
-
84874596625
-
Phase II trial of bevacizumab (B) and ixabepilone (Ix) for advanced non-squamous NSCLC progressive after first-line therapy
-
abstract e
-
Sanborn RE, Mack PC, Beckett L. Phase II trial of bevacizumab (B) and ixabepilone (Ix) for advanced non-squamous NSCLC progressive after first-line therapy. J Clin Oncol 2012;30(Suppl):abstract e 13550
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
, pp. 13550
-
-
Sanborn, R.E.1
Mack, P.C.2
Beckett, L.3
-
25
-
-
33644831567
-
Phase i dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors
-
Rubin E, Rothermel J, Tesfaye F, et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 2005;23:9120-9
-
(2005)
J Clin Oncol
, vol.23
, pp. 9120-9129
-
-
Rubin, E.1
Rothermel, J.2
Tesfaye, F.3
-
26
-
-
0000155381
-
A phase i clinical and pharmacokinetic study of EPO906 (Epothilone B), given every three weeks, in patients with advanced solid tumors
-
abstract
-
Calvert P, O'Neill V, Twelves C, et al. A phase I clinical and pharmacokinetic study of EPO906 (Epothilone B), given every three weeks, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001;20:abstract 429
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
, pp. 429
-
-
Calvert, P.1
O'Neill, V.2
Twelves, C.3
-
27
-
-
57049125514
-
Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC): A phase I/II trial
-
abstract
-
Sanchez J, Mellemgaard A, Perry M, et al. Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC): a phase I/II trial. Proc Amer Soc Clin Oncol 2006;24:abstract 7104
-
(2006)
Proc Amer Soc Clin Oncol
, vol.24
, pp. 7104
-
-
Sanchez, J.1
Mellemgaard, A.2
Perry, M.3
-
28
-
-
78751546627
-
Activity of patupilone in advanced or metastatic non-small cell lung cancer: A phase II study [abstract]
-
Zatloukal P, Mellemgaard A, Sanchez JM, et al. Activity of patupilone in advanced or metastatic non-small cell lung cancer: a phase II study [abstract]. Ann Oncol 2008;19(8S):296P
-
(2008)
Ann Oncol
, vol.19
, Issue.8 S
-
-
Zatloukal, P.1
Mellemgaard, A.2
Sanchez, J.M.3
-
29
-
-
58749099669
-
Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label, multicenter, phase II study
-
abstract
-
Abrey L, Wen P, Govindan R, et al. Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II study. J Clin Oncol 2008;26(15S):abstract 2033
-
(2008)
J Clin Oncol
, vol.26
, Issue.15 S
, pp. 2033
-
-
Abrey, L.1
Wen, P.2
Govindan, R.3
-
30
-
-
33646547391
-
A phase i study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors
-
abstract
-
Schmid P, Kiewe P, Kuehnhardt D, et al. A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors. J Clin Oncol 2005;23:abstract 2051
-
(2005)
J Clin Oncol
, vol.23
, pp. 2051
-
-
Schmid, P.1
Kiewe, P.2
Kuehnhardt, D.3
-
31
-
-
42549103468
-
Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer
-
Gatzemeier U, von Pawel J, Eschbach C, et al. Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer. EJC Suppl 2007;5(4):378
-
(2007)
EJC Suppl
, vol.5
, Issue.4
, pp. 378
-
-
Gatzemeier, U.1
Von Pawel, J.2
Eschbach, C.3
-
32
-
-
0032416734
-
Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel
-
DOI 10.1073/pnas.95.26.15798
-
Chou T, Zhang X, Harris C, et al. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci USA 1998;95:15798-802 (Pubitemid 29018780)
-
(1998)
Proceedings of the National Academy of Sciences of the United States of America
, vol.95
, Issue.26
, pp. 15798-15802
-
-
Chou, T.-C.1
Zhang, X.-G.2
Harris, C.R.3
Kuduk, S.D.4
Balog, A.5
Savin, K.A.6
Bertino, J.R.7
Danishefsky, S.J.8
-
33
-
-
8344260820
-
Phase i study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors
-
abstract
-
Holen K, Syed S, Hannah A, et al. Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors. Proc Amer Soc Clin Oncol 2004;23:abstract 2024
-
(2004)
Proc Amer Soc Clin Oncol
, vol.23
, pp. 2024
-
-
Holen, K.1
Syed, S.2
Hannah, A.3
-
34
-
-
3142755834
-
KOS-862 (Epothilone D): Phase 1 dose escalating and pharmacokinetic (PK) study in patients with advanced malignancies
-
abstract
-
Spriggs D, Dupont J, Pezzulli A, et al. KOS-862 (Epothilone D): phase 1 dose escalating and pharmacokinetic (PK) study in patients with advanced malignancies. Proc Amer Soc Clin Oncol 2003;22:abstract 894
-
(2003)
Proc Amer Soc Clin Oncol
, vol.22
, pp. 894
-
-
Spriggs, D.1
Dupont, J.2
Pezzulli, A.3
-
35
-
-
2442505920
-
KOS-862 (epothilone D): A comparison of two schedules in patients with advanced malignancies
-
abstract
-
Piro L, Rosen L, Parson M, et al. KOS-862 (epothilone D): a comparison of two schedules in patients with advanced malignancies. Proc Amer Soc Clin Oncol 2003;22:abstract 539
-
(2003)
Proc Amer Soc Clin Oncol
, vol.22
, pp. 539
-
-
Piro, L.1
Rosen, L.2
Parson, M.3
-
36
-
-
31344455354
-
A phase II study of KOS-862 (Epothilone D) as second-line therapy in non-small cell lung cancer
-
abstract
-
Yee L, Lynch T, Villalona-Calero M, et al. A phase II study of KOS-862 (Epothilone D) as second-line therapy in non-small cell lung cancer. Proc Amer Soc Clin Oncol 2005;23:abstract 7127
-
(2005)
Proc Amer Soc Clin Oncol
, vol.23
, pp. 7127
-
-
Yee, L.1
Lynch, T.2
Villalona-Calero, M.3
-
37
-
-
84855686899
-
A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer
-
Spira AI, Iannotti NO, Savin MA, et al. A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer. Clin Lung Cancer 2012;13(1):31-8
-
(2012)
Clin Lung Cancer
, vol.13
, Issue.1
, pp. 31-38
-
-
Spira, A.I.1
Iannotti, N.O.2
Savin, M.A.3
-
38
-
-
84863831074
-
Eribulin mesylate (E7389) review of efficacy and tolerability in breast, pancreatic, head and neck, and non small cell lung cancer
-
Scarpace SL. Eribulin mesylate (E7389) review of efficacy and tolerability in breast, pancreatic, head and neck, and non small cell lung cancer. Clin Ther 2012;34(7):1467-73
-
(2012)
Clin Ther
, vol.34
, Issue.7
, pp. 1467-1473
-
-
Scarpace, S.L.1
-
39
-
-
58149189433
-
Aurora kinases: Structure, functions and their association with cancer
-
Kollareddy M, Dzubak P, Zheleva D, Hajduch M. Aurora kinases: structure, functions and their association with cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008;152(1):27-33.27
-
(2008)
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
, vol.152
, Issue.1
, pp. 27-33
-
-
Kollareddy, M.1
Dzubak, P.2
Zheleva, D.3
Hajduch, M.4
-
40
-
-
76649120544
-
Aurora kinase inhibitors-Rising stars in cancer therapeutics?
-
Dar AA, Goff LW, Majid S, et al. Aurora kinase inhibitors-rising stars in cancer therapeutics? Mol Cancer Ther 2010;9:268-78
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 268-278
-
-
Dar, A.A.1
Goff, L.W.2
Majid, S.3
-
41
-
-
0037084163
-
-/- cells
-
DOI 10.1093/emboj/21.4.483
-
Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/-cells. EMBO J 2002;21:483-92 (Pubitemid 34174030)
-
(2002)
EMBO Journal
, vol.21
, Issue.4
, pp. 483-492
-
-
Meraldi, P.1
Honda, R.2
Nigg, E.A.3
-
42
-
-
33750374052
-
A phase i clinical and pharmacokinetic (pk) trial of the aurora kinase (ak) inhibitor mk-0457 in cancer patients
-
abstract
-
Rubin E, Shapiro G, Stein M, et al. A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients. Proc Amer Soc Clin Oncol 2006;24:abstract 3009
-
(2006)
Proc Amer Soc Clin Oncol
, vol.24
, pp. 3009
-
-
Rubin, E.1
Shapiro, G.2
Stein, M.3
-
43
-
-
70349156095
-
Phase i pharmacokinetic (pk) and pharmacodynamic (pd) study of the selective aurora a kinase (aak) inhibitor mln8054 in patients (pts) with advanced solid tumors
-
abstract
-
Macarulla T, Rodr?guez-Braun E, Tabernero J, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the selective aurora A kinase (AAK) inhibitor MLN8054 in patients (pts) with advanced solid tumors. J Clin Oncol 2009;27(15s Suppl):abstract 2578
-
(2009)
J Clin Oncol
, vol.27
, Issue.15 SUPPL.
, pp. 2578
-
-
Macarulla, T.1
Rodrguez-Braun, E.2
Tabernero, J.3
-
44
-
-
70349156095
-
Phase i pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective aurora A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors
-
abstract
-
Cervantes-Ruiperez A, Elez ME, Rosello S, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective aurora A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 2009;15s Suppl):abstract 2565
-
(2009)
J Clin Oncol
, Issue.15 SUPPL.
, pp. 2565
-
-
Cervantes-Ruiperez, A.1
Elez, M.E.2
Rosello, S.3
-
45
-
-
84874626828
-
Phase i/ii study of the investigational aurora a kinase (aak) inhibitor mln8237 (alisertib) in patients (pts) with non-small cell lung cancer (nsclc), small cell lung cancer (sclc), breast cancer (brc), head/neck cancer (h&n), and gastroesophageal (ge) adenocarcinoma: Preliminary phase ii results
-
SMay 20
-
Lee P, Alvarez RH, Melichar B, et al. Phase I/II study of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in patients (pts) with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer (BrC), head/neck cancer (H&N), and gastroesophageal (GE) adenocarcinoma: preliminary phase II results. 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2012;30(15S May 20 Suppl):3010
-
(2012)
2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol
, vol.30
, Issue.15 SUPPL.
, pp. 3010
-
-
Lee, P.1
Alvarez, R.H.2
Melichar, B.3
-
46
-
-
84874620450
-
Relationship of Aurora-A kinase and EGFR inhibition in non-small cell lung cancer (NSCLC) cell lines
-
abstract
-
Zhang J, Pan X, Astsaturov IA, et al. Relationship of Aurora-A kinase and EGFR inhibition in non-small cell lung cancer (NSCLC) cell lines. J Clin Oncol 2011;29(Suppl):abstract e13038
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Zhang, J.1
Pan, X.2
Astsaturov, I.A.3
-
47
-
-
70249137888
-
A phase i study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors
-
abstract
-
Kristeleit R, Calvert H, Arkenau H, et al. A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol 2009;27(15s Suppl):abstract 2566
-
(2009)
J Clin Oncol
, vol.27
, Issue.15 SUPPL.
, pp. 2566
-
-
Kristeleit, R.1
Calvert, H.2
Arkenau, H.3
-
48
-
-
80054109912
-
Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC
-
Medema RH, Lin CC, Yang JC. Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. Clin Cancer Res 2011;17:6459-66
-
(2011)
Clin Cancer Res
, vol.17
, pp. 6459-6466
-
-
Medema, R.H.1
Lin, C.C.2
Yang, J.C.3
-
49
-
-
1842372659
-
Polo-like kinase, a novel marker for cellular proliferation
-
Yuan J, Horlin A, Hock B, et al. Polo-like kinase, a novel marker for cellular proliferation. Am J Pathol 1997;150:1165-72 (Pubitemid 27152634)
-
(1997)
American Journal of Pathology
, vol.150
, Issue.4
, pp. 1165-1172
-
-
Yuan, J.1
Horlin, A.2
Hock, B.3
Stutte, H.J.4
Rubsamen-Waigmann, H.5
Strebhardt, K.6
-
50
-
-
0031051218
-
Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer
-
Wolf G, Elez R, Doermer A, et al. Prognostic significance of polo-like kinase (PLK) expression in non small cell lung cancer. Oncogene 1997;14:543-9 (Pubitemid 27090956)
-
(1997)
Oncogene
, vol.14
, Issue.5
, pp. 543-549
-
-
Wolf, G.1
Elez, R.2
Doermer, A.3
Holtrich, U.4
Ackermann, H.5
Stutte, H.J.6
Altmannsberger, H.-M.7
Rubsamen-Waigmann, H.8
Strebhardt, K.9
-
51
-
-
0035990398
-
Expression of polo-like kinase (PLK1) in thin melanomas: A novel marker of metastatic disease
-
Kneisel L, Strebhardt K, Bernd A, et al. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002;29:354-8
-
(2002)
J Cutan Pathol
, vol.29
, pp. 354-358
-
-
Kneisel, L.1
Strebhardt, K.2
Bernd, A.3
-
52
-
-
16844369144
-
Small interfering RNA-mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals
-
DOI 10.1158/0008-5472.CAN-04-2131
-
Guan R, Tapang P, Leverson JD, et al. Small interfering RNA-mediated pololike kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005;65:2698-704 (Pubitemid 40490070)
-
(2005)
Cancer Research
, vol.65
, Issue.7
, pp. 2698-2704
-
-
Guan, R.1
Tapang, P.2
Leverson, J.D.3
Albert, D.4
Giranda, V.L.5
Luo, Y.6
-
53
-
-
68049095649
-
A phase i dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC)
-
abstract
-
Ellis PM, Chu QS, Leighl NB, et al. A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26(Suppl):abstract 8115
-
(2008)
J Clin Oncol
, vol.26
, Issue.SUPPL.
, pp. 8115
-
-
Ellis, P.M.1
Chu, Q.S.2
Leighl, N.B.3
-
54
-
-
77954423900
-
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: Results from an open-label, randomized phase II clinical trial
-
Sebastian M, Reck M, Waller CF, et al. The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol 2010;5:1060-7
-
(2010)
J Thorac Oncol
, vol.5
, pp. 1060-1067
-
-
Sebastian, M.1
Reck, M.2
Waller, C.F.3
-
55
-
-
84857120350
-
Final analysis of a phase i single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors
-
abstract
-
Gil T, Schoffski P, Awada A, et al. Final analysis of a phase I single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors. J Clin Oncol 2010;28(Suppl 15):abstract 3061
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL. 15
, pp. 3061
-
-
Gil, T.1
Schoffski, P.2
Awada, A.3
-
56
-
-
84874606380
-
Phase i trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors
-
abstract
-
Dumez H, Gombos A, Schoffski P, et al. Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors. J Clin Oncol 2012;30(Suppl): abstract 3018
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Dumez, H.1
Gombos, A.2
Schoffski, P.3
-
57
-
-
0037673498
-
Kinesin Superfamily Proteins (KIFs) in the mouse transcriptome
-
DOI 10.1101/gr.984503
-
Miki H, Setou M, Hirokawa N. Kinesin superfamily proteins (KIFs) in the mouse transcriptome. Genome Res 2003;13:1455-65 (Pubitemid 36827242)
-
(2003)
Genome Research
, vol.13
, Issue.6 B
, pp. 1455-1465
-
-
Miki, H.1
Setou, M.2
Arakawa, T.3
Carninci, P.4
Kawai, J.5
Hayashizaki, Y.6
Hirokawa, N.7
-
58
-
-
33846558079
-
Differential gene expression analysis of kinesin spindle protein in human solid tumors
-
abstract
-
Hegde P, Cogswell J, Carrick K, et al. Differential gene expression analysis of kinesin spindle protein in human solid tumors. Proc Amer Soc Clin Oncol 2003;22:abstract 535
-
(2003)
Proc Amer Soc Clin Oncol
, vol.22
, pp. 535
-
-
Hegde, P.1
Cogswell, J.2
Carrick, K.3
-
60
-
-
20344406651
-
Phase i trial of novel kinesin spindle protein (ksp) inhibitor sb-715992 iv q 21 days
-
abstract
-
Chu Q, Holen K, Rowinsky E, et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days. Proc Amer Soc Clin Oncol 2004;22:abstract 2078
-
(2004)
Proc Amer Soc Clin Oncol
, vol.22
, pp. 2078
-
-
Chu, Q.1
Holen, K.2
Rowinsky, E.3
-
61
-
-
33845318699
-
Phase i study of ispinesib in combination with carboplatin in patients with advanced solid tumors
-
S June 20
-
Jones SF, Plummer ER, Burris HA, et al. Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S June 20 Suppl):2027
-
(2006)
2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol
, vol.24
, Issue.18 SUPPL.
, pp. 2027
-
-
Jones, S.F.1
Plummer, E.R.2
Burris, H.A.3
-
62
-
-
84874625448
-
-
Cytokinetics Reports Data for Ispinesib (SB-715992) in Platinum-Sensitive Non- Small Cell Lung Cancer
-
Cytokinetics Reports Data for Ispinesib (SB-715992) in Platinum-Sensitive Non- Small Cell Lung Cancer. Available from: http://www.prnewswire.com/ newsreleases/cytokinetics-reports-data-forispinesib- sb-715992-in- platinumsensitive- non-small-cell-lung-cancer- 70742202.html
-
-
-
|